Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Lebanon National Health Strategy-Vision 2030



Lebanon National Health Strategy – Vision 2030- Two Year Review
Lebanon National Health Strategy – Vision 2030- One Year Review

Introduction

In January 2023, the Ministry of Public Health (MoPH) launched its National Health Strategy: Vision 2030. Vision 2030 set out the framework for a sustained and modernized recovery of the health sector and intended to address the challenges of leading a burned-out health system. Through this strategy, and under the leadership of the MoPH, the different partners of the health sector joined efforts to respond to the escalating unmet health needs and participate in building a stronger, more resilient health system.

Over the past year, the National Health Strategy has made significant strides in enhancing the overall well-being of the population. The multifaceted approach has addressed key issues such as human resources shortage, challenged healthcare accessibility, and the massive gaps in health financing. Despite the multiple predicaments in the country, including the ongoing war and hostilities; the economic collapse and financial meltdown; the extended refugee crisis with its associated increased demand for scarce health resources; and disease outbreaks such as cholera; the health sector remained steady, and determined in achieving progress across the objectives outlined in the National Health Strategy. The National Health Strategy’s commitment to fostering advanced governance and financing mechanisms, investing in essential public health functions, strengthening primary healthcare, capacitating human resources, and embracing digital health technologies is expected to result in an advanced, more equitable, more inclusive, and more sustainable healthcare delivery.(Read More...)
 
Lebanon National Health Strategy: Vision 2030
 
Executive Summary

Lebanon is passing through one of the most severe and complex crises in its recent history, caused by the interplay of political turbulence, socioeconomic meltdown, and the lingering COVID-19 pandemic. Regionally, conflict and instability continue to result in the influx of refugees, which constitute now around one third of the Lebanese population.

The intertwined crises Lebanon has been suffering from unmasked the effects of pre-existing health system inefficiencies, including the predominance of tertiary care over preventive and primary care; a weakened public health sector; a pluralistic financing system; and a supply-induced demand with unsustainable and unrealistic expectations. The synergistic effects of these crises amplified the malfunctioning of a disrupted health system, rendering a system notorious for its resilience at the verge of a breakdown. As a result, the ability to respond to the increased needs of a growing population was deterred. Equitable access to care was exceptionally difficult for people with vulnerabilities. Worsening in health outcomes was noted at many fronts: life expectancy, maternal mortality, under 5 mortality, and childhood vaccination. Previously forgotten diseases such as diphtheria, tetanus, and most recently cholera re-emerged, and the health gains of previous years have started to fade away.

The multifaceted crisis has also severely impacted access to and utilization of healthcare services. The percentage of households with difficulty accessing health care rose from 25% to 36% within around 4 months during the year 2020. Hospitalizations, particularly for surgeries, diminished by 30% in 2021, and the average monthly hospitalization days decreased by 25%. The cost of treatments, medical consultations, or transportation to health facilities have become prohibitive to many, resulting in delayed presentation of patients for medical attention, who at many times presented with decompensated or non-salvageable conditions. Duly, challenged access to specialized healthcare was coupled with an exponential increased demand on the services provided by the Primary Health Care Network. With crisis, an opportunity has emerged for repositioning primary health care as a gateway for affordable, quality promotive, preventive, and primary health services, and for moving closer towards achieving Universal Health Coverage.

The recent drain of human resources particularly those with high competencies and specialization has become an increasing concern, with more than 20% of nurses and around 40% of doctors having already left the country. Additionally, the layoffs, salary cuts and closures of pharmacies and the reduced activities of hospitals which accompanied the economic crisis, deleteriously affected the healthcare workforce. This shortage in qualified human resources endangered the quality and availability of health care services.

The pharmaceutical sector was also hit hard by the crisis. In 2020, the government’s policy of relying on external sources for medications and medical supplies, coupled the economic crisis, led to drops in imports, resulting in severe market shortages. This has paved the way to hoarding, smuggling, black market practices, and the entry of illegal, low-quality drugs and supplies into the country.(Read More...)


ِAnnexes:
    ...
    151
    ...
ATC Name B/G Ingredients Dosage Form Price
D06AA04 MEPHICYCLINE DERMIQUE G Tetracycline HCl - 3% 3% Ointment 145,903 L.L
J01AA08 VULGA XR G Minocycline - 105mg 105mg Tablet, film coated 3,682,128 L.L
J05AG03 STOVIRENZ G Efavirenz - 600mg 600mg Tablet, film coated 6,857,456 L.L
L01EA01 IMATINIB GP PHARM G Imatinib - 400mg 400mg Tablet, coated 26,083,945 L.L
N01AX03 KETAMINE PANPHARMA G Ketamine HCl - 250mg/5ml 250mg/5ml Injectable solution 1,534,668 L.L
N03AX14 LEPITAM G Levetiracetam - 250mg 250mg Tablet 700,078 L.L
N05BA12 ALPROX G Alprazolam - 1mg 1mg Tablet 895,895 L.L
P02CA03 ANDAZOL G Albendazole - 200mg 6 Tablet, film coated 302,365 L.L
R06AA52 HISTALIX G Diphenhydramine HCl - 14mg/5ml, Ammonium chloride - 135mg/5ml, Menthol - 1.1mg/5ml Syrup 405,840 L.L
V07AB01 ARWAN WFI G Water for injection - Water for injection, irrigation 399,915 L.L
A03FA07 GAROPRIDE G Itopride Hydrochloride - 50mg 50mg Tablet, film coated 213,671 L.L
A10BB12 GLYPRIDE G Glimepiride - 4mg 4mg Tablet 657,139 L.L
B01AB11 ANGIOFLUX G Sulodexide - 250LRU 250LRU Capsule, soft 2,026,514 L.L
B05BB02 DEXTROSE 5% SODIUM CHLORIDE 0.9% INJECTION, USP G Sodium chloride - 0.9%, Glucose - 5% Injectable solution 194,211 L.L
C01BC04 FLECAINIDE BIOGARAN L.P. G Flecainide acetate - 100mg 100mg Capsule, extended release 1,154,361 L.L
C08CA05 NIFE-PAR G Nifedipine - 5mg/ml 5mg/ml Solution 36,667,942 L.L
C09DX01 VIOSTAN AM PLUS 160/10/25 G Valsartan - 160mg, Amlodipine - 10mg, Hydrochlorothiazide - 25mg Tablet, film coated 1,196,020 L.L
D06AA04 TETRACYCLINE OINTMENT G Tetracycline HCl - 3% 3% Ointment 107,507 L.L
J01AA08 VULGA XR G Minocycline - 80mg 80mg Tablet, film coated 2,832,820 L.L
J01DI02 ZINFORO G Ceftaroline fosamil - 600mg 600mg Injectable powder for concentrate for solution 44,995,862 L.L
L01EA01 IMATINIB NEAPOLIS G Imatinib - 400mg 400mg Tablet, film coated 36,046,335 L.L
M01AB05 CLOREN G Diclofenac sodium - 12.5mg 12.5mg Suppository 353,239 L.L
N03AX14 LEVETIRACETAM ARROW LAB G Levetiracetam - 250mg 250mg Tablet, film coated, breakable 1,243,054 L.L
N05BA12 TRANQUINAL 0.5 SUBLINGUAL G Alprazolam - 0.5mg 0.5mg Tablet, sublingual 459,594 L.L
R06AA52 MENTEX G Diphenhydramine HCl - 12.5mg/5ml, Dextrometorphan HBr - 15mg/5ml, Pseudoephedrine HCl - 30mg/5ml Syrup 323,866 L.L
V07AB01 EAU POUR PREPARATION INJ. G Water for injection - Water for injection, irrigation 3,385,139 L.L
A03FA08 CINITREX G Cinitapride - 1mg 1mg Tablet 636,981 L.L
A10BB12 JOSWE GLEMAX 4 G Glimepiride - 4mg 4mg Caplet 593,978 L.L
B01AB12 HIBOR G Bemiparin Sodium - 2,500IU 2,500IU Injectable solution 704,173 L.L
B05BB02 DEXTROSE 5% SODIUM CHLORIDE 0.9% INJECTION, USP G Sodium chloride - 0.9%, Glucose - 5% Injectable solution 180,421 L.L
    ...
    151
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025